A Phase II Study to Assess All-trans Retinoic Acid and Tetra-arsenic Tetra-sulphide Formula with Venetoclax for the Treatment of Acute Promyelocytic Leukemia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066592

Enrollment

Unknown

Registered

2022-12-09

Start date

2022-12-12

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Promyelocytic Leukemia

Interventions

Test group:ATRA plus RIF and Venetoclax

Eligibility

Sex/Gender

All

Age

16 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 16-80 years ; 2.Confirmed as APL with t ( 15 ; 17 ) ( q22 ; q12 ) and newly diagnosed patients with PML-RARa ( detected by cytogenetics or RT-PCR ) ;

Exclusion criteria

Exclusion criteria: 1. Patients with severe liver function or renal insufficiency ( serum creatinine > 2.5 times the upper limit of normal serum total bilirubin = 2 times the upper limit of normal ALT and AST > 3 times the upper limit of normal that was not related to APL) or cardiac insufficiency ( EF480ms excluding electrolyte disturbances ) 2.Combined with other malignant tumors 3.Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Complete molecular remission rate;Cumulative incidence of relapse;	—

Secondary

Measure	Time frame
Time to complete remission;Early death rate;2 year event-free survival ;	—

Countries

China

Contacts

Public ContactHuaiyu Wang

First Affiliated Hospital of Xian Jiaotong University

whymed@126.com+86 18991232410

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026